Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%)

Mark Ballow; M. Berger; F. A. Bonilla; R. H. Buckley; C. H. Cunningham-Rundles; P. Fireman; M. Kaliner; H. D. Ochs; S. Skoda-Smith; M. T. Sweetser; H. Taki; C. Lathia

doi:10.1046/j.1423-0410.2003.00286.x

Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%)

Mark Ballow, M. Berger, F. A. Bonilla, R. H. Buckley, C. H. Cunningham-Rundles, P. Fireman, M. Kaliner, H. D. Ochs, S. Skoda-Smith, M. T. Sweetser, H. Taki, C. Lathia

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Background and Objectives: A new intravenous immunoglobulin (IGIV) process has been developed that integrates efficient inactivation of enveloped virus, using caprylate, with immunoglobulin G (IgG) purification and caprylate removal by column chromatography. Two clinical studies were conducted to compare the pharmacokinetics of the new product, IGIV-C, 10% (Gamunex™, 10%), formulated with glycine, with the licensed solvent-detergent (SD)-treated intravenous immunoglobulin IGIV-SD, 10% (Gamimune

Original language	English
Pages (from-to)	202-210
Number of pages	9
Journal	Vox Sanguinis
Volume	84
Issue number	3
DOIs	https://doi.org/10.1046/j.1423-0410.2003.00286.x
State	Published - Apr 2003

Keywords

Gamma globulin
IVIG
Immunoglobulin
Pharmacokinetics
Primary immunodeficiency

Access to Document

10.1046/j.1423-0410.2003.00286.x

Cite this

Ballow, M., Berger, M., Bonilla, F. A., Buckley, R. H., Cunningham-Rundles, C. H., Fireman, P., Kaliner, M., Ochs, H. D., Skoda-Smith, S., Sweetser, M. T., Taki, H., & Lathia, C. (2003). Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%). Vox Sanguinis, 84(3), 202-210. https://doi.org/10.1046/j.1423-0410.2003.00286.x

@article{68e4fb2f3d1348d0ad74c5681bb3d8f1,

title = "Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex{\texttrademark}, 10%)",

abstract = "Background and Objectives: A new intravenous immunoglobulin (IGIV) process has been developed that integrates efficient inactivation of enveloped virus, using caprylate, with immunoglobulin G (IgG) purification and caprylate removal by column chromatography. Two clinical studies were conducted to compare the pharmacokinetics of the new product, IGIV-C, 10% (Gamunex{\texttrademark}, 10%), formulated with glycine, with the licensed solvent-detergent (SD)-treated intravenous immunoglobulin IGIV-SD, 10% (Gamimune",

keywords = "Gamma globulin, IVIG, Immunoglobulin, Pharmacokinetics, Primary immunodeficiency",

author = "Mark Ballow and M. Berger and Bonilla, {F. A.} and Buckley, {R. H.} and Cunningham-Rundles, {C. H.} and P. Fireman and M. Kaliner and Ochs, {H. D.} and S. Skoda-Smith and Sweetser, {M. T.} and H. Taki and C. Lathia",

year = "2003",

month = apr,

doi = "10.1046/j.1423-0410.2003.00286.x",

language = "English",

volume = "84",

pages = "202--210",

journal = "Vox Sanguinis",

issn = "0042-9007",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "3",

}

Ballow, M, Berger, M, Bonilla, FA, Buckley, RH, Cunningham-Rundles, CH, Fireman, P, Kaliner, M, Ochs, HD, Skoda-Smith, S, Sweetser, MT, Taki, H & Lathia, C 2003, 'Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%)', Vox Sanguinis, vol. 84, no. 3, pp. 202-210. https://doi.org/10.1046/j.1423-0410.2003.00286.x

TY - JOUR

T1 - Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%)

AU - Ballow, Mark

AU - Berger, M.

AU - Bonilla, F. A.

AU - Buckley, R. H.

AU - Cunningham-Rundles, C. H.

AU - Fireman, P.

AU - Kaliner, M.

AU - Ochs, H. D.

AU - Skoda-Smith, S.

AU - Sweetser, M. T.

AU - Taki, H.

AU - Lathia, C.

PY - 2003/4

Y1 - 2003/4

N2 - Background and Objectives: A new intravenous immunoglobulin (IGIV) process has been developed that integrates efficient inactivation of enveloped virus, using caprylate, with immunoglobulin G (IgG) purification and caprylate removal by column chromatography. Two clinical studies were conducted to compare the pharmacokinetics of the new product, IGIV-C, 10% (Gamunex™, 10%), formulated with glycine, with the licensed solvent-detergent (SD)-treated intravenous immunoglobulin IGIV-SD, 10% (Gamimune

AB - Background and Objectives: A new intravenous immunoglobulin (IGIV) process has been developed that integrates efficient inactivation of enveloped virus, using caprylate, with immunoglobulin G (IgG) purification and caprylate removal by column chromatography. Two clinical studies were conducted to compare the pharmacokinetics of the new product, IGIV-C, 10% (Gamunex™, 10%), formulated with glycine, with the licensed solvent-detergent (SD)-treated intravenous immunoglobulin IGIV-SD, 10% (Gamimune

KW - Gamma globulin

KW - IVIG

KW - Immunoglobulin

KW - Pharmacokinetics

KW - Primary immunodeficiency

UR - http://www.scopus.com/inward/record.url?scp=0037398124&partnerID=8YFLogxK

U2 - 10.1046/j.1423-0410.2003.00286.x

DO - 10.1046/j.1423-0410.2003.00286.x

M3 - Article

C2 - 12670369

AN - SCOPUS:0037398124

SN - 0042-9007

VL - 84

SP - 202

EP - 210

JO - Vox Sanguinis

JF - Vox Sanguinis

IS - 3

ER -

Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%)

Abstract

Keywords

Access to Document

Fingerprint

Cite this